Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower pain (visual analogue scale) compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Clinical remission · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes clinical remission (14 days) compared with placebo (very low certainty).
1 finding from 1 review
Clinical improvement (Rachmilewitz index) (14 days) · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Very low
Total adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · people with active UC
Antibiotics showed no clear difference in failure to induce clinical remission at end of study compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · people with active UC
It is very uncertain whether antibiotics changes failure to induce clinical response at end of study compared with 5‐ASA (very low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
1 finding from 1 review
Failure to induce clinical remission at end of study · people with active UC
It is very uncertain whether antibiotics changes failure to induce clinical remission at end of study compared with probiotics (very low certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
1 finding from 1 review
Failure to maintain clinical remission at end of study · Patients with quiescent ulcerative colitis
It is very uncertain whether antibiotics changes failure to maintain clinical remission at end of study compared with 5‐ASA (very low certainty).
1 finding from 1 review
Failure to maintain clinical response · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review